These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 15236622

  • 1. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL.
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [Abstract] [Full Text] [Related]

  • 2. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
    Urban AW, Bean P, Aziz D, Graziano FM, Neudeck BL.
    Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
    [Abstract] [Full Text] [Related]

  • 3. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS.
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [Abstract] [Full Text] [Related]

  • 4. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.
    BMC Infect Dis; 2006 Jul 11; 6():107. PubMed ID: 16834769
    [Abstract] [Full Text] [Related]

  • 5. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.
    Ther Drug Monit; 2008 Oct 11; 30(5):604-10. PubMed ID: 18728627
    [Abstract] [Full Text] [Related]

  • 6. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.
    Wateba MI, Billaud E, Dailly E, Jolliet P, Raffi F.
    HIV Med; 2006 Apr 11; 7(3):197-9. PubMed ID: 16494635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S, Rickenbach M, Popescu M, Taffe P, Craig C, Perrin L, Swiss HIV Cohort Study.
    Antivir Ther; 2001 Sep 11; 6(3):185-9. PubMed ID: 11808753
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V, Hocht C, Mangano A, Niselman V, Mariño Hernández E, Cáceres Guido P, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF.
    Pharmacology; 2009 Sep 11; 83(1):59-66. PubMed ID: 19052483
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis CR, Pontali E, Papa L, Miletich F, Bassetti D.
    Clin Infect Dis; 2003 Jun 01; 36(11):1476-82. PubMed ID: 12766843
    [Abstract] [Full Text] [Related]

  • 14. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
    Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D, French Hospital Database on HIV, ANRS C04.
    Antivir Ther; 2007 Jun 01; 12(3):317-24. PubMed ID: 17591021
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V, Lindkvist A, Bergroth T, Knut L, Sönnerborg A.
    J Med Virol; 2005 Aug 01; 76(4):447-51. PubMed ID: 15977242
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth-Mai E, Jessen A, Burger D, Rockstroh JK.
    Eur J Med Res; 2007 Jul 26; 12(7):289-94. PubMed ID: 17933700
    [Abstract] [Full Text] [Related]

  • 19. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
    Danel C, Moh R, Peytavin G, Anzian A, Minga A, Gomis OB, Seri B, Nzunettu G, Gabillard D, Salamon R, Bissagnene E, Anglaret X.
    AIDS Res Hum Retroviruses; 2007 Jan 26; 23(1):62-6. PubMed ID: 17263634
    [Abstract] [Full Text] [Related]

  • 20. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A.
    Antimicrob Agents Chemother; 2002 Dec 26; 46(12):3877-82. PubMed ID: 12435691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.